# Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

> **NCT01247922** · PHASE2 · TERMINATED · sponsor: **OSI Pharmaceuticals** · enrollment: 4 (actual)

## Conditions studied

- Ependymoma

## Interventions

- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT01247922
- **Lead sponsor:** OSI Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05-23
- **Primary completion:** 2012-09-13
- **Final completion:** 2012-09-13
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety concerns. As a result, the companion trial, OSI-774-206 has been stopped
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01247922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01247922, "Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01247922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*